Exploring the potential of bi-specific antibodies in cancer immunotherapy

Bi-specific antibodies (BsAbs) represent a groundbreaking advancement in cancer immunotherapy, offering a novel approach to target and eliminate cancer cells by engaging two distinct antigens simultaneously. This review delves into the mechanistic foundations and clinical applications of BsAbs, highlighting their unique dual-targeting capabilities that bridge immune cells with malignant cells to enhance anti-tumor activity. We discuss the various types and design strategies of BsAbs, including their modular structures and engineering innovations that have propelled their efficacy and specificity. The review also examines preclinical and clinical trial data, showcasing the promising results and success stories in different cancer types. Despite their potential, BsAbs face challenges such as manufacturing complexities, stability issues, and toxicity concerns, which we explore alongside current solutions and regulatory considerations. By integrating the latest advancements and emerging trends, this review provides a comprehensive overview of BsAbs and their transformative role in the future of cancer therapy.